* Pulmonx Corp LUNG.OQ reported a quarterly adjusted loss
of 36
cents per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -42
cents. The mean expectation of five analysts for the quarter
was for a loss of 46 cents per share. Wall Street expected
results to range from -50 cents to -40 cents per share.
* Revenue rose 29.7% to $18.85 million from a year ago;
analysts
expected $17.89 million.
* Pulmonx Corp's reported EPS for the quarter was a loss
of 36
cents.
* The company reported a quarterly loss of $13.75 million.
* Pulmonx Corp shares had fallen by 16.7% this quarter and
lost 39.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Pulmonx Corp is
$15.00
This summary was machine generated from LSEG data May 2 at 05:30
a.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.46 -0.36 Beat
Dec. 31 2023 -0.41 -0.36 Beat
Sep. 30 2023 -0.43 -0.39 Beat
Jun. 30 2023 -0.44 -0.43 Beat